209 related articles for article (PubMed ID: 25854528)
1. Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study.
van Galen KPM; Sanders YV; Vojinovic U; Eikenboom J; Cnossen MH; Schutgens REG; van der Bom JG; Fijnvandraat K; Laros-Van Gorkom BAP; Meijer K; Leebeek FWG; Mauser-Bunschoten EP;
Haemophilia; 2015 May; 21(3):e185-e192. PubMed ID: 25854528
[TBL] [Abstract][Full Text] [Related]
2. Joint assessment in von Willebrand disease. Validation of the Haemophilia Joint Health score and Haemophilia Activities List.
van Galen KPM; Timmer MA; de Kleijn P; Fischer K; Foppen W; Schutgens REG; Eikenboom J; Meijer K; Cnossen MH; Fijnvandraat K; van der Bom JG; Laros-van Gorkom BAP; Leebeek FWG; Mauser-Bunschoten EP; Win Study Group OBOT
Thromb Haemost; 2017 Aug; 117(8):1465-1470. PubMed ID: 28492695
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Outcome after Joint Bleeds in Von Willebrand Disease Compared to Haemophilia A: A Post Hoc Analysis.
van Galen KPM; Timmer M; de Kleijn P; Leebeek FWG; Foppen W; Schutgens REG; Eikenboom J; Meijer K; Fijnvandraat K; Laros-van Gorkom BAP; Twisk JW; Mauser-Bunschoten EP; Fischer K;
Thromb Haemost; 2018 Oct; 118(10):1690-1700. PubMed ID: 30273954
[TBL] [Abstract][Full Text] [Related]
4. Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study.
van Galen KPM; de Kleijn P; Foppen W; Eikenboom J; Meijer K; Schutgens REG; Fischer K; Cnossen MH; de Meris J; Fijnvandraat K; van der Bom JG; Laros-van Gorkom BAP; Leebeek FWG; Mauser-Bunschoten EP;
Haematologica; 2017 Sep; 102(9):1486-1493. PubMed ID: 28572165
[TBL] [Abstract][Full Text] [Related]
5. Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease.
Atiq F; Meijer K; Eikenboom J; Fijnvandraat K; Mauser-Bunschoten EP; van Galen KPM; Nijziel MR; Ypma PF; de Meris J; Laros-van Gorkom BAP; van der Bom JG; de Maat MP; Cnossen MH; Leebeek FWG;
Br J Haematol; 2018 Jul; 182(1):93-105. PubMed ID: 29767844
[TBL] [Abstract][Full Text] [Related]
6. Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease.
Metjian AD; Wang C; Sood SL; Cuker A; Peterson SM; Soucie JM; Konkle BA;
Haemophilia; 2009 Jul; 15(4):918-25. PubMed ID: 19473418
[TBL] [Abstract][Full Text] [Related]
7. von Willebrand disease and aging: an evolving phenotype.
Sanders YV; Giezenaar MA; Laros-van Gorkom BA; Meijer K; van der Bom JG; Cnossen MH; Nijziel MR; Ypma PF; Fijnvandraat K; Eikenboom J; Mauser-Bunschoten EP; Leebeek FW;
J Thromb Haemost; 2014 Jul; 12(7):1066-75. PubMed ID: 24750783
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience of prophylactic treatment in von Willebrand disease.
Lethagen S
Thromb Res; 2006; 118 Suppl 1():S9-11. PubMed ID: 16616322
[TBL] [Abstract][Full Text] [Related]
9. Impact of von Willebrand disease on health-related quality of life in a pediatric population.
de Wee EM; Fijnvandraat K; de Goede-Bolder A; Mauser-Bunschoten EP; Eikenboom JC; Brons PP; Smiers FJ; Tamminga R; Oostenbrink R; Raat H; van der Bom JG; Leebeek FW;
J Thromb Haemost; 2011 Mar; 9(3):502-9. PubMed ID: 21166992
[TBL] [Abstract][Full Text] [Related]
10. Hemophilic arthropathy in patients with von Willebrand disease.
van Galen KP; Mauser-Bunschoten EP; Leebeek FW
Blood Rev; 2012 Nov; 26(6):261-6. PubMed ID: 23010260
[TBL] [Abstract][Full Text] [Related]
11. Clinical, economic, and health-related quality of life burden associated with von Willebrand disease in adults and children: Systematic and targeted literature reviews.
Castaman G; Katsarou O; Jansen N; Santos S; Escolar G; Berntorp E
Haemophilia; 2023 Mar; 29(2):411-422. PubMed ID: 36097135
[TBL] [Abstract][Full Text] [Related]
12. Joint surgery in von Willebrand disease: a multicentre cross-sectional study.
van Galen KPM; Meijer K; Vogely HC; Eikenboom J; Schutgens REG; Cnossen MH; Fijnvandraat K; van der Bom JG; Laros-van Gorkom BAP; Leebeek FWG; Mauser-Bunschoten EP;
Haemophilia; 2016 Mar; 22(2):256-262. PubMed ID: 26551280
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
Miller CH; Kelley L; Green D
Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
[TBL] [Abstract][Full Text] [Related]
14. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease.
Gill JC; Shapiro A; Valentino LA; Bernstein J; Friedman C; Nichols WL; Manco-Johnson M
Haemophilia; 2011 Nov; 17(6):895-905. PubMed ID: 21535320
[TBL] [Abstract][Full Text] [Related]
15. von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease.
Sanders YV; Groeneveld D; Meijer K; Fijnvandraat K; Cnossen MH; van der Bom JG; Coppens M; de Meris J; Laros-van Gorkom BA; Mauser-Bunschoten EP; Leebeek FW; Eikenboom J;
Blood; 2015 May; 125(19):3006-13. PubMed ID: 25673639
[TBL] [Abstract][Full Text] [Related]
16. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease.
de Wee EM; Sanders YV; Mauser-Bunschoten EP; van der Bom JG; Degenaar-Dujardin ME; Eikenboom J; de Goede-Bolder A; Laros-van Gorkom BA; Meijer K; Hamulyák K; Nijziel MR; Fijnvandraat K; Leebeek FW;
Thromb Haemost; 2012 Oct; 108(4):683-92. PubMed ID: 22918553
[TBL] [Abstract][Full Text] [Related]
17. Orthopaedic surgery in patients with von Willebrand disease.
Siboni SM; Biguzzi E; Solimeno LP; Pasta G; Mistretta C; Mannucci PM; Peyvandi F
Haemophilia; 2014 Jan; 20(1):133-40. PubMed ID: 23992395
[TBL] [Abstract][Full Text] [Related]
18. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease.
Gill JC; Castaman G; Windyga J; Kouides P; Ragni M; Leebeek FW; Obermann-Slupetzky O; Chapman M; Fritsch S; Pavlova BG; Presch I; Ewenstein B
Blood; 2015 Oct; 126(17):2038-46. PubMed ID: 26239086
[TBL] [Abstract][Full Text] [Related]
19. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
20. A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.
Peyvandi F; Castaman G; Gresele P; De Cristofaro R; Schinco P; Bertomoro A; Morfini M; Gamba G; Barillari G; Jiménez-Yuste V; Königs C; Iorio A; Federici AB
Blood Transfus; 2019 Sep; 17(5):391-398. PubMed ID: 30747707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
